Initially, the FDA issued complete response letters on October 22, 2024, and April 18, 2024, citing deficiencies classified as minor, and requested that the manufacturer address these with new and updated information and clarifications related to the drug substance, drug product, manufacturing, and microbiology
Patients with type 2 diabetes, insulin resistance, or those looking to lose a significant amount of weight are often good candidates for the program
The liver benefits are particularly noteworthy
pTeroPure is a registered trademark of ChromaDex, Inc
Frequently Asked Questions Can I move my Wegovy injection day by just a few days
Theyre delicate and typically require refrigeration or specific stabilization to be effective